Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PepGNP-COVID19 in healthy adults
NCT05633446Phase 2Not yet recruiting
- Sponsor
- Gylden Pharma
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Peptides, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PepGNP-COVID19 in coronavirus disease 2019 (COVID-19), sponsored by Gylden Pharma. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
PepGNP-COVID19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05633446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633446.